Peter J. Leedman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter J. Leedman has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Andrew Barker
3 shared publicationsKeith M. Giles
3 shared publicationsMichael R. Epis
Laboratory for Cancer Medicine, Western Australian Institute for Medical Research and University of Western Australia Centre for Medical Research, Royal Perth Hospital, Perth, Western Australia 6000, Australia
2 shared publicationsShane M Colley
2 shared publications- Shane M. Colley
Laboratory for Cancer Medicine, The University of Western Australia Centre for Medical Research, Western Australian Institute for Medical Research, Perth, Australia
2 shared publications Andrew Davidson
1 shared publication
Latest Publications
- 6 February 2012
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (4_Suppleme) , B7
Abstract B7: ETS1 overexpression in prostate cancer cells
The ETS1 transcription factor is overexpressed in human prostate cancers in comparison to nonmalignant prostate and exhibits nuclear, in addition to aberrant cytoplasmic localisation. A previous report has identified direct interaction between ETS1 and the androgen receptor (AR) in the prostate cancer cell line, LNCaP and we have demonstrated that this ligand-dependent interaction is mediated via the ETS (DNA binding) domain of ETS1 and the ligand-binding domain of the AR. In a cohort of 44 prostate cancer cases, mRNA for the full-length ETS1 isoform, p54ETS1 was detected in all prostate tumour and adjacent nonmalignant prostate tissues, while expression of the internally truncated p42ETS1 isoform was very low or undetectable. In protein lysates extracted from the same cases, p54ETS1 was detected in all samples, with expression of a lower molecular weight ETS1 corresponding in size to the dominant negative p27ETS1 isoform also observed. Increased expression of one or both of the ETS1 isoforms was identified in 38 (86%) cases, supporting the elevated expression of ETS1 in human prostate tumours. Both ETS1 and the AR upregulate expression of the prostatic tumour suppressor, NKX3.1 via sequences located in the 5′ promoter and 3′ untranslated region (3′UTR), respectively. Although unresponsive to androgens, the proximal ∼2kb of the NKX3.1 promoter, and in particular a 76bp sequence surrounding the ETS binding site (EBS) become androgen responsive following ETS1 overexpression. In addition, in LNCaP cells that stably overexpress p54ETS1, the biphasic proliferative responses to androgens, where low (≤10−10M) DHT concentrations stimulate proliferation and higher (>10−10M) DHT levels inhibit proliferation, were altered and DHT concentrations as low as 10−12M inhibited proliferation. The findings indicate that the increased expression of ETS1 commonly observed in human prostate tumours may modify the androgen responsiveness of the cancer cells, augmenting AR-mediated regulation of androgen target genes and potentially sensitising prostate cancer cells to the very low androgen levels in men treated with androgen ablation therapies.
- 6 February 2012
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (4_Suppleme) , B7
Abstract B7: ETS1 overexpression in prostate cancer cells
The ETS1 transcription factor is overexpressed in human prostate cancers in comparison to nonmalignant prostate and exhibits nuclear, in addition to aberrant cytoplasmic localisation. A previous report has identified direct interaction between ETS1 and the androgen receptor (AR) in the prostate cancer cell line, LNCaP and we have demonstrated that this ligand-dependent interaction is mediated via the ETS (DNA binding) domain of ETS1 and the ligand-binding domain of the AR. In a cohort of 44 prostate cancer cases, mRNA for the full-length ETS1 isoform, p54ETS1 was detected in all prostate tumour and adjacent nonmalignant prostate tissues, while expression of the internally truncated p42ETS1 isoform was very low or undetectable. In protein lysates extracted from the same cases, p54ETS1 was detected in all samples, with expression of a lower molecular weight ETS1 corresponding in size to the dominant negative p27ETS1 isoform also observed. Increased expression of one or both of the ETS1 isoforms was identified in 38 (86%) cases, supporting the elevated expression of ETS1 in human prostate tumours. Both ETS1 and the AR upregulate expression of the prostatic tumour suppressor, NKX3.1 via sequences located in the 5′ promoter and 3′ untranslated region (3′UTR), respectively. Although unresponsive to androgens, the proximal ∼2kb of the NKX3.1 promoter, and in particular a 76bp sequence surrounding the ETS binding site (EBS) become androgen responsive following ETS1 overexpression. In addition, in LNCaP cells that stably overexpress p54ETS1, the biphasic proliferative responses to androgens, where low (≤10−10M) DHT concentrations stimulate proliferation and higher (>10−10M) DHT levels inhibit proliferation, were altered and DHT concentrations as low as 10−12M inhibited proliferation. The findings indicate that the increased expression of ETS1 commonly observed in human prostate tumours may modify the androgen responsiveness of the cancer cells, augmenting AR-mediated regulation of androgen target genes and potentially sensitising prostate cancer cells to the very low androgen levels in men treated with androgen ablation therapies.
- Open Access
- 1 December 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (48) , 41442-41454
The RNA-binding Protein HuR Opposes the Repression of ERBB-2 Gene Expression by MicroRNA miR-331-3p in Prostate Cancer Cells
- 1 December 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (48) , 41442-41454
Open AccessThe RNA-binding Protein HuR Opposes the Repression of ERBB-2 Gene Expression by MicroRNA miR-331-3p in Prostate Cancer Cells
- 1 June 2011
- Published by The Endocrine Society
- p. P1-30
SLIRP, a Nuclear Receptor Coregulator, Is a Good Prognostic Factor in Colorectal Cancer
Colorectal cancer (CRC) is the second leading source of cancer morbidity in the Western world, accounting for 52,000 deaths in the United States per annum. Key pathways that drive CRC growth include the Notch and beta-catenin networks. Although a variety of nuclear receptors (NRs) have been implicated in CRC pathogenesis and response to treatment, little is known of the role of NR coregulators in this disease. Previously we discovered SLIRP, a Steroid receptor RNA Activator (SRA)-binding NR coregulator, which is a potent repressor of NR transcriptional activity. We have also generated data in other systems showing that SLIRP can regulate the Notch signaling pathway. Consequently, in these studies we investigated the expression of SLIRP in human CRC and its potential to modulate NR and Notch signaling. Using a human CRC tissue microarray cohort of 1044 patients (Stage 2 and 3 tumors) and four independent mRNA CRC patient microarray databases, we found that elevated SLIRP expression was significantly associated with a higher 5-year survival and lower relapse rate (p<0.001). In addition, SLIRP expression was strongly inversely associated with tumor stage and lymph node invasion. When SLIRP expression in human CRC cells was reduced with siRNA invasion (using matrigel assays) and Notch signaling (using a HES-1 luciferase reporter) both were significantly increased. Furthermore, CRC cells treated with SLIRP siRNA were more resistant in growth assays to the baseline CRC chemotherapeutic agent, 5-Fluorouracil (5-FU). Taken together, these data provide the first evidence that SLIRP is a good prognostic factor in CRC and suggest that this protective effect may in part be due to suppression of Notch signalling, reduced invasion and enhanced chemotherapeutic sensitivity. Sources of Research Support: NHMRC, RPH Medical Research Foundation and Cancer Council of WA. Nothing to Disclose: PAC, SMC, MP, AD, BI, LS, BW, AR, PJL
- 1 June 2011
- Published by The Endocrine Society
- p. P1-30
SLIRP, a Nuclear Receptor Coregulator, Is a Good Prognostic Factor in Colorectal Cancer
Colorectal cancer (CRC) is the second leading source of cancer morbidity in the Western world, accounting for 52,000 deaths in the United States per annum. Key pathways that drive CRC growth include the Notch and beta-catenin networks. Although a variety of nuclear receptors (NRs) have been implicated in CRC pathogenesis and response to treatment, little is known of the role of NR coregulators in this disease. Previously we discovered SLIRP, a Steroid receptor RNA Activator (SRA)-binding NR coregulator, which is a potent repressor of NR transcriptional activity. We have also generated data in other systems showing that SLIRP can regulate the Notch signaling pathway. Consequently, in these studies we investigated the expression of SLIRP in human CRC and its potential to modulate NR and Notch signaling. Using a human CRC tissue microarray cohort of 1044 patients (Stage 2 and 3 tumors) and four independent mRNA CRC patient microarray databases, we found that elevated SLIRP expression was significantly associated with a higher 5-year survival and lower relapse rate (p<0.001). In addition, SLIRP expression was strongly inversely associated with tumor stage and lymph node invasion. When SLIRP expression in human CRC cells was reduced with siRNA invasion (using matrigel assays) and Notch signaling (using a HES-1 luciferase reporter) both were significantly increased. Furthermore, CRC cells treated with SLIRP siRNA were more resistant in growth assays to the baseline CRC chemotherapeutic agent, 5-Fluorouracil (5-FU). Taken together, these data provide the first evidence that SLIRP is a good prognostic factor in CRC and suggest that this protective effect may in part be due to suppression of Notch signalling, reduced invasion and enhanced chemotherapeutic sensitivity. Sources of Research Support: NHMRC, RPH Medical Research Foundation and Cancer Council of WA. Nothing to Disclose: PAC, SMC, MP, AD, BI, LS, BW, AR, PJL
- 1 June 2011
- Published by The Endocrine Society
- p. P1-31
Loss of the Nuclear Receptor Corepressor SLIRP Compromises Male Fertility In Vivo
Nuclear receptors (NRs) and their coregulators play fundamental roles in initiating and directing gene expression influencing mammalian reproduction, development and metabolism. SRA stem Loop Interacting RNA-binding Protein (SLIRP) is a Steroid receptor RNA Activator (SRA) RNA binding protein which is a potent repressor of NR activity. SLIRP is present in NR complexes associated with NR target genes in the nucleus, however, it is also abundant in mitochondria where it may affect energy turnover. Notably, SLIRP is a potent regulator of androgen action and is expressed in the testis and more specifically within developing spermatozoa. Colocalization studies indicate SLIRP is present within the mid-piece and head of the mature sperm suggesting a functional role within this tissue. To investigate the in vivo effects of SLIRP, we have generated a SLIRP knock out (KO) mouse. This animal is viable, however when homozygous males are crossed with wild type (wt) or heterozygous females the resultant litter size is reduced by approximately one quarter (−/− x +/+, 4.8 pups/litter; −/− x −/+, 6.3) compared with those produced by wt males with comparable females (+/+ x +/+, 6.6; +/+ x −/+, 6.7). Comparison of sperm samples from males of each of the phenotypes showed that the KO mice had 60% fewer progressively motile sperm than either the wt or homozygous mice. In humans, micro-array data suggests that SLIRP mRNA levels in sperm from teratozoospermic men are frequently reduced. In sum, our data suggests that loss of SLIRP results in impaired male fertility, attributable in part, to compromised sperm motility. Nothing to Disclose: SMC, RS, LW, VR, RCF, SS, KD, BG, BS, LWS, MO, BWO, PJL
- 1 June 2011
- Published by The Endocrine Society
- p. P1-31
Loss of the Nuclear Receptor Corepressor SLIRP Compromises Male Fertility In Vivo
Nuclear receptors (NRs) and their coregulators play fundamental roles in initiating and directing gene expression influencing mammalian reproduction, development and metabolism. SRA stem Loop Interacting RNA-binding Protein (SLIRP) is a Steroid receptor RNA Activator (SRA) RNA binding protein which is a potent repressor of NR activity. SLIRP is present in NR complexes associated with NR target genes in the nucleus, however, it is also abundant in mitochondria where it may affect energy turnover. Notably, SLIRP is a potent regulator of androgen action and is expressed in the testis and more specifically within developing spermatozoa. Colocalization studies indicate SLIRP is present within the mid-piece and head of the mature sperm suggesting a functional role within this tissue. To investigate the in vivo effects of SLIRP, we have generated a SLIRP knock out (KO) mouse. This animal is viable, however when homozygous males are crossed with wild type (wt) or heterozygous females the resultant litter size is reduced by approximately one quarter (−/− x +/+, 4.8 pups/litter; −/− x −/+, 6.3) compared with those produced by wt males with comparable females (+/+ x +/+, 6.6; +/+ x −/+, 6.7). Comparison of sperm samples from males of each of the phenotypes showed that the KO mice had 60% fewer progressively motile sperm than either the wt or homozygous mice. In humans, micro-array data suggests that SLIRP mRNA levels in sperm from teratozoospermic men are frequently reduced. In sum, our data suggests that loss of SLIRP results in impaired male fertility, attributable in part, to compromised sperm motility. Nothing to Disclose: SMC, RS, LW, VR, RCF, SS, KD, BG, BS, LWS, MO, BWO, PJL
- 1 December 2010
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 10 (6) , 655-661
Regulation of ErbB receptor signalling in cancer cells by microRNA
- 1 December 2010
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 10 (6) , 655-661
Regulation of ErbB receptor signalling in cancer cells by microRNA
- Open Access
- 1 September 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (37) , 24696-24704
miR-331-3p Regulates ERBB-2 Expression and Androgen Receptor Signaling in Prostate Cancer
- 1 September 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (37) , 24696-24704
Open AccessmiR-331-3p Regulates ERBB-2 Expression and Androgen Receptor Signaling in Prostate Cancer
- Open Access
- 1 February 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (9) , 5731-5741
Regulation of Epidermal Growth Factor Receptor Signaling in Human Cancer Cells by MicroRNA-7
- 1 February 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (9) , 5731-5741
Open AccessRegulation of Epidermal Growth Factor Receptor Signaling in Human Cancer Cells by MicroRNA-7
- 1 February 2009
- Published by Taylor & Francis in Critical Reviews in Biochemistry and Molecular Biology
- Vol. 44 (1) , 25-33
SRA and its binding partners: an expanding role for RNA-binding coregulators in nuclear receptor-mediated gene regulation
The discovery that SRA RNA can function as a nuclear receptor (NR) coactivator resulted in a fundamental change in the perception of how NRs and their coregulators may regulate hormone signaling pathways. The subsequent identification of molecules capable of binding SRA, including SHARP, p68, and more recently SLIRP, which also function as coregulators, has further broadened our understanding of NR-dependent gene regulation. The integral role that NRs play in directing developmental, metabolic and pathological programs of transcription has defined them as paramount targets for treating a broad range of human diseases. Thus with a greater understanding of SRA and its interactions with its binding partners, novel RNA–protein interactions may be identified and exploited for therapeutic gain. Here we discuss the isolation of SRA, its impact on NR activity and interactions with known binding partners.
- 1 February 2009
- Published by Taylor & Francis in Critical Reviews in Biochemistry and Molecular Biology
- Vol. 44 (1) , 25-33
SRA and its binding partners: an expanding role for RNA-binding coregulators in nuclear receptor-mediated gene regulation
The discovery that SRA RNA can function as a nuclear receptor (NR) coactivator resulted in a fundamental change in the perception of how NRs and their coregulators may regulate hormone signaling pathways. The subsequent identification of molecules capable of binding SRA, including SHARP, p68, and more recently SLIRP, which also function as coregulators, has further broadened our understanding of NR-dependent gene regulation. The integral role that NRs play in directing developmental, metabolic and pathological programs of transcription has defined them as paramount targets for treating a broad range of human diseases. Thus with a greater understanding of SRA and its interactions with its binding partners, novel RNA–protein interactions may be identified and exploited for therapeutic gain. Here we discuss the isolation of SRA, its impact on NR activity and interactions with known binding partners.
- 19 February 2008
- Published by Wiley in IUBMB Life
- Vol. 60 (3) , 159-164
The RNA coregulator SRA, its binding proteins and nuclear receptor signaling activity
Nuclear receptor (NR) coregulators are key modulators of hormone signaling. Discovery of steroid receptor RNA activator (SRA), a coregulator that is active as a RNA, transformed thinking in the field of hormone action. The subsequent identification of SRA‐binding coregulator proteins, including p68, SHARP and more recently SLIRP, has provided important insight into SRA's mechanism of action and potentially offers new opportunities to target NR signaling pathways for therapeutic gain. Here we outline advances in the field of NR coregulator biology, with a bias on recent progress in understanding SRA‐protein interactions. © 2008 IUBMB IUBMB Life, 60(3): 159–164, 2008
- 19 February 2008
- Published by Wiley in IUBMB Life
- Vol. 60 (3) , 159-164
The RNA coregulator SRA, its binding proteins and nuclear receptor signaling activity
Nuclear receptor (NR) coregulators are key modulators of hormone signaling. Discovery of steroid receptor RNA activator (SRA), a coregulator that is active as a RNA, transformed thinking in the field of hormone action. The subsequent identification of SRA‐binding coregulator proteins, including p68, SHARP and more recently SLIRP, has provided important insight into SRA's mechanism of action and potentially offers new opportunities to target NR signaling pathways for therapeutic gain. Here we outline advances in the field of NR coregulator biology, with a bias on recent progress in understanding SRA‐protein interactions. © 2008 IUBMB IUBMB Life, 60(3): 159–164, 2008